Chronic Schizophrenia
Conditions
Interventions
control group:placebo
Sponsors
Kangci Hospital of Jiaxing
Eligibility
Sex/Gender
All
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: 1. Male or female patient aged 16-60 years were included in the study if they fulfilled the diagnostic criteria for schizophrenia of ICD-10; 2. at least 10 years duration of schizophrenia; 3. a minimum required severity of negative symptoms defined as a score of = 3 on at least two of the five global rating items of Scale for the Assessment of SANS 4. no obvious positive symptoms 5. Hamilton Depression Scale-17 Items (HAMD-17) score =7 and Hamilton Anxiety Scale (HAMA) =7
Exclusion criteria
Exclusion criteria: 1. cognitive impairments or negative symptoms due to other diseases 2. patients receiving first-generation antipsychotics due to the possibility of drug-induced negative symptoms; 3. history of neurologic diseases; 4. any other serious mental illness other than schizophrenia as a primary diagnosis 5. participants with clear inflammatory conditions due to infection, autoimmune diseases or other reasons 6. contraindications of berberine
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Scale for the Assessment of Negative Symptoms; | — |
Secondary
| Measure | Time frame |
|---|---|
| Trail-making Test A;Trail-making Test B;Hopkins Verbal Learning Test;serum level of interleukin-1ß;serum level of interleukin-6;serum level of tumor necrosis factor-a; | — |
Countries
China
Contacts
Public ContactPu Zhengping
Kangci Hospital of Jiaxing
Outcome results
None listed